Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Mestre-Ferrandiz

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Pharmacoeconomics|January 21, 2020
Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine PricesBrendan Shaw, Jorge Mestre-Ferrandiz
Pharmacoeconomics|January 22, 2016
Biosimilars: How Can Payers Get Long-Term Savings?Jorge Mestre-Ferrandiz, Adrian Towse, Mikel Berdud
Health Economics|December 12, 2013
Value-based differential pricing: efficient prices for drugs in a global contextPatricia Danzon, Adrian Towse, Jorge Mestre-Ferrandiz
Health Policy (Amsterdam, Netherlands)|November 4, 2018
Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in AndalusiaJulieta Casanova-Juanes, Jorge Mestre-Ferrandiz, Jaime Espín-Balbino
Pharmacoeconomics|September 11, 2018
Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?Jorge Mestre-Ferrandiz, Néboa Zozaya, Bleric Alcalá, et al.
Drug Discovery Today|January 4, 2025
Academic Drug Discovery Units in the UK: Progress and challengesMichael M Hopkins, Jorge Mestre-Ferrandiz, Phillipa Crane, et al.
Frontiers in Public Health|October 4, 2024
Collaboration for new therapies: maximizing health and innovationJorge Mestre-Ferrandiz, Pierre Meulien, Dennis A Ostwald, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 7, 2020
Does NICE influence the adoption and uptake of generics in the UK?Victoria Serra-Sastre, Simona Bianchi, Jorge Mestre-Ferrandiz, et al.
Pharmacoeconomics|September 17, 2013
Projecting expenditure on medicines in the UK NHSPhill O'Neill, Jorge Mestre-Ferrandiz, Ruth Puig-Peiro, et al.
Orphanet Journal of Rare Diseases|December 13, 2019
An analysis of orphan medicine expenditure in Europe: is it sustainable?Jorge Mestre-Ferrandiz, Christina Palaska, Tom Kelly, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Pharmacoeconomics|January 21, 2020
Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine PricesBrendan Shaw, Jorge Mestre-Ferrandiz
Pharmacoeconomics|January 22, 2016
Biosimilars: How Can Payers Get Long-Term Savings?Jorge Mestre-Ferrandiz, Adrian Towse, Mikel Berdud
Health Economics|December 12, 2013
Value-based differential pricing: efficient prices for drugs in a global contextPatricia Danzon, Adrian Towse, Jorge Mestre-Ferrandiz
Health Policy (Amsterdam, Netherlands)|November 4, 2018
Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in AndalusiaJulieta Casanova-Juanes, Jorge Mestre-Ferrandiz, Jaime Espín-Balbino
Pharmacoeconomics|September 11, 2018
Multi-Indication Pricing: Nice in Theory but Can it Work in Practice?Jorge Mestre-Ferrandiz, Néboa Zozaya, Bleric Alcalá, et al.
Drug Discovery Today|January 4, 2025
Academic Drug Discovery Units in the UK: Progress and challengesMichael M Hopkins, Jorge Mestre-Ferrandiz, Phillipa Crane, et al.
Frontiers in Public Health|October 4, 2024
Collaboration for new therapies: maximizing health and innovationJorge Mestre-Ferrandiz, Pierre Meulien, Dennis A Ostwald, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 7, 2020
Does NICE influence the adoption and uptake of generics in the UK?Victoria Serra-Sastre, Simona Bianchi, Jorge Mestre-Ferrandiz, et al.
Pharmacoeconomics|September 17, 2013
Projecting expenditure on medicines in the UK NHSPhill O'Neill, Jorge Mestre-Ferrandiz, Ruth Puig-Peiro, et al.
Orphanet Journal of Rare Diseases|December 13, 2019
An analysis of orphan medicine expenditure in Europe: is it sustainable?Jorge Mestre-Ferrandiz, Christina Palaska, Tom Kelly, et al.
Pageof 5